Samplix, the Birkerød, Denmark-based droplet microfluidics company founded in 2013, secured a €25 million (~$27.0M) first closing of a new financing round targeting €30 million total, comprising €3 million in new capital and €22 million in shareholder convertible bonds. The round was led by privately-owned European investment firm WLanholding GmbH with participation from all major shareholders and remains open to additional investors; WLanholding founder Dr. Werner Lanthaler, former CEO of Evotec, will join Samplix's Board within the next year. The article disclosed no specific revenue, client count, pipeline or employee metrics beyond noting its Xdrop platform is used by biopharmaceutical companies and academic institutions worldwide, and the company intends to use proceeds to strengthen its balance sheet and broaden commercial scale of the Xdrop platform and deepen biopharma/academia partnerships.